		 standardized difference 	ence digoxin vs placebo 🔳 stand	terdized difference presc. digoxin vs no digoxin			
characteristic	rand. digoxin	rand. placebo	p-value		prescr. digoxin	no digoxin	p-value
age at randomization (years)	63.42 ± 11.02	63.55 ± 10.81	0.6274	•	63.29 ± 10.90	63.64 ± 10.93	0.1828
female gender	755 (22.23%)	764 (22.45%)	0.8235	• •	699 (23.17%)	820 (21.68%)	0.1420
nonwhite race	487 (14.34%)	504 (14.81%)	0.5794	• •	471 (15.61%)	520 (13.75%)	0.0303
heart rate (beats/minute)	78.60 ± 12.68	78.91 ± 12.63	0.3123	••	78.78 ± 12.47	78.74 ± 12.81	0.9041
systolic blood pressure (mm Hg)	125.57 ± 19.94	126.02 ± 19.94	0.3485	••	125.23 ± 19.74	126.25 ± 20.08	0.0361
diastolic blood pressure (mm Hg)	74.89 ± 11.47	74.91 ± 11.06	0.9446	•	73.97 ± 11.13	75.65 ± 11.31	<.0001
BMI (kg/m^2)	27.00 ± 5.19	27.23 ± 5.19	0.0790	• •	26.51 ± 4.99	27.59 ± 5.30	<.0001
serum creatinine (mg/dl)	1.28 ± 0.37	1.29 ± 0.37	0.3911	<u> </u>	1.28 ± 0.37	1.29 ± 0.37	0.4038
potassium (mmol/l)	4.33 ± 0.51	4.32 ± 0.50	0.2385	•	4.30 ± 0.54	4.34 ± 0.48	0.0010
clinical features of CHF							
ischemic primary cause of CHF	2405 (70.99%)	2398 (70.65%)	0.7638	• •	2071 (68.85%)	2732 (72.39%)	0.0014
duration of CHF (months) (Median and IQR)	17.00 (36.00)	16.00 (35.00)	0.2627	•	24.00 (40.00)	12.00 (32.00)	<.0001
left ventricular ejection fraction (%)	28.63 ± 8.85	28.45 ± 8.85	0.3795	•	27.74 ± 8.84	29.18 ± 8.81	<.0001
chest X-ray (CT-ratio) >0.55	1176 (34.62%)	1170 (34.38%)	0.8369	• •	1117 (37.02%)	1229 (32.49%)	<.0001
NYHA III or IV	1118 (32.95%)	1105 (32.49%)	0.6863	• •	1049 (34.78%)	1174 (31.07%)	0.0012
current angina	922 (27.15%)	899 (26.43%)	0.5004	• •	769 (25.49%)	1052 (27.82%)	0.0308
signs and symptoms of CHF (past and/or present)							
rales	2403 (70.78%)	2434 (71.55%)	0.4860	• •	2249 (74.57%)	2588 (68.45%)	<.0001
elevated jugular venous pressure	1783 (52.52%)	1772 (52.10%)	0.7313	• •	1725 (57.21%)	1830 (48.40%)	<.0001
peripheral edema	1783 (52.52%)	1745 (51.31%)	0.3182	• •	1680 (55.72%)	1848 (48.88%)	<.0001
dyspnea at rest or orthopnea	2376 (69.99%)	2402 (70.63%)	0.5631	• •	2242 (74.39%)	2536 (67.05%)	<.0001
dyspnea at exertion	3232 (95.23%)	3244 (95.38%)	0.7599	• •	2890 (95.92%)	3586 (94.82%)	0.0332
limitation of activity	3156 (92.99%)	3154 (92.74%)	0.6888	• •	2822 (93.63%)	3488 (92.25%)	0.0283
S3	1716 (50.57%)	1696 (49.90%)	0.5765	• •	1727 (57.34%)	1685 (44.58%)	<.0001
pulmonary congestion	2252 (66.35%)	2327 (68.44%)	0.0663	•	2132 (70.74%)	2447 (64.74%)	<.0001
number of symptoms	5.51 ± 2.07	5.52 ± 2.03	0.8132	•	5.79 ± 1.96	5.29 ± 2.09	<.0001
medical history							
previous myocardial infarction	2198 (64.72%)	2221 (65.27%)	0.6390	• •	1917 (63.54%)	2502 (66.16%)	0.0247
diabetes	961 (28.29%)	972 (28.56%)	0.8027	•	868 (28.77%)	1065 (28.15%)	0.5746
hypertension	1527 (44.96%)	1557 (45.75%)	0.5135	• •	1306 (43.30%)	1778 (47.00%)	0.0023
medication							
ACE inhibitors	3197 (94.11%)	3225 (94.77%)	0.2372	• •	2865 (94.96%)	3557 (94.03%)	0.0942
nitrates (oral or paste)	1432 (42.15%)	1466 (43.08%)	0.4407	e e	1265 (41.93%)	1633 (43.17%)	0.3052
hydrazaline	77 (2.27%)	64 (1.88%)	0.2640	••	77 (2.55%)	64 (1.69%)	0.0134
diuretics	2759 (81.22%)	2797 (82.19%)	0.2992	•	2662 (88.23%)	2894 (76.50%)	<.0001
previous digoxin use	1498 (44.10%)	1519 (44.64%)	0.6544	•			
study medication							
randomized digoxin				•	1498 (48.65%)	1899 (50.20%)	0.6544
recommended digoxin dose (mg/day)	0.27 ± 0.07	0.27 ± 0.07	0.7846	• •	0.26 ± 0.06	0.27 ± 0.07	<.0001
prescribed dose of study medication (mg/day)	0.24 ± 0.07	0.24 ± 0.07	0.4455	• •	0.24 ± 0.07	0.25 ± 0.07	<.0001
				A4 43 A9 A4 A A1 A9 A4			

Appendix 1: more detailed version of Figure 2 with details on baseline characteristics